432 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma

Gelijkaardige items

• 432 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma
  door: Merrick Ross, et al.
  Gepubliceerd in: (2020-11-01)
• Inflammatory Colitis after Treatment of Melanoma with Talimogene Laherparepvec (T-VEC)
  door: Jennifer Gardner, et al.
  Gepubliceerd in: (2018-07-01)
• Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
  door: Ann W. Silk, et al.
  Gepubliceerd in: (2016-09-01)
• Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
  door: Erika Richtig, et al.
  Gepubliceerd in: (2021-02-01)
• Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells
  door: Jens Tijtgat, et al.
  Gepubliceerd in: (2021-10-01)